3 days ago

India’s CDMO Sector Highlights Three Pharma Stocks to Watch

Pharmaceutical companies sometimes hire other companies to help develop and make medicines.

These businesses are called CDMOs.

The article says Indian CDMOs are getting more work as drugmakers diversify where they produce medicines.

It discusses Laurus Labs, Divi’s Laboratories and Akums Drugs and Pharma.

Each company reported recent business or financial developments.

Laurus reported higher revenue, while Divi’s reported higher income and profit compared with the year-earlier quarter.

Akums said its CDMO business helped drive growth.

The article also notes that companies are investing in new manufacturing capacity.

It cautions readers to check a company’s finances and risks before investing.

Key facts

Companies covered: Laurus Labs, Divi’s Laboratories and Akums Drugs and Pharma
Sector: Pharmaceutical contract development and manufacturing organizations (CDMOs)
Laurus Labs Q1 FY27 revenue: Rs 20.26 billion, up 29%
Divi’s Laboratories Q1 FY27 consolidated income: Rs 31.44 billion, compared with Rs 25.29 billion in the corresponding quarter a year earlier
Divi’s Laboratories Q1 FY27 profit after tax: Rs 9.02 billion, compared with Rs 5.45 billion in the corresponding quarter a year earlier
Akums Q1 FY27 growth: Revenue grew by over 13% and EBITDA by more than 30%; the article says the CDMO segment primarily led growth.
Investment caveat: The article is informational, not a stock recommendation, and advises assessing fundamentals, regulatory records and valuation.

financialexpress.com · 3 days ago